Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + cisplatin + TS-1
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Pembrolizumab + cisplatin + TS-1** is a combination regimen used mainly in clinical trials for advanced or metastatic gastric and gastroesophageal junction cancer, specifically in HER2-negative, PD-L1-positive patients. Pembrolizumab is a monoclonal antibody acting as an immune checkpoint inhibitor targeting PD-1, thereby enhancing the immune system’s response against tumor cells. Cisplatin is a platinum-based chemotherapeutic agent causing DNA cross-linking and apoptosis in cancer cells. TS-1 (also known as S-1) is an oral fluoropyrimidine derivative that inhibits DNA synthesis by interfering with thymidylate synthase activity. This combination aims to leverage immune-mediated anti-tumor activity and direct cytotoxicity for improved outcomes in gastric cancer patients. Its use has demonstrated promising efficacy and manageable safety in phase II studies among Japanese patients with advanced gastric/gastroesophageal junction cancer[3][2][1].
- Other names
- pembrolizumab + cisplatin + TS-1pembrolizumab + SPpembrolizumab + S-1 + cisplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on pembrolizumab + cisplatin + TS-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + cisplatin + TS-1.